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Abstract 
Dexmedetomidine (Dex), a highly selective α2-adrenergic receptor agonist, has been shown to attenuate systemic 
inflammatory response induced by lipopolysaccharide (LPS). The protective effects of Dex may reportedly be due to 
the activation of the α7 nicotinic acetylcholine receptor (α7nAChR)-dependent cholinergic anti-inflammatory path-
way. Spleen has been shown to play a pivotal role in the neural cholinergic anti-inflammatory pathway. However, little 
is known about the specific function of spleen in the protective effects of Dex against sepsis. To investigate the role 
of spleen in the treatment of Dex against sepsis, we studied the effects of preemptive administration of Dex to septic 
mice on the NF-κB p65 activation and downstream pro-inflammatory cytokine expression in the spleen. Our results 
provided evidence that Dex treatment attenuated LPS-activated NF-κB p65 activation, as well as the production of 
tumor necrosis factor-α, interleukin-6, and interleukin-1β at the level of both mRNA and protein in spleen. Conse-
quently, serum concentrations of these cytokines decreased. Conversely, preemptive injection of α-bungarotoxin, a 
selective α7nAChR antagonist, reversed these effects of Dex. Our findings indicated that spleen played a critical role 
in the protective effects of Dex against sepsis and provided further insight into the anti-inflammatory mechanisms of 
Dex.
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Background
Sepsis is a condition characterized by uncontrolled infec-
tion and affects many organs, with an attendant high 
mortality rate (Angus et al. 2001). The onset and perpetu-
ation of sepsis involve the up-regulation of NF-κB (Mül-
ler et al. 1993) and a complex network of cytokines, such 
as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), 
and interleukin-1β (IL-1β) (Beutler and Cerami 1989; 
Durum et  al. 1985; Hofer et  al. 2009; Wong and Clark 
1988). The unbalanced overproduction of these media-
tors provokes overwhelming inflammation responses and 
eventual lethal multiple-organ failure. Therefore, reduc-
ing excessive inflammation cytokine production during 
sepsis is beneficial to relieve the excessive inflammatory 
responses of septic mice.
Dexmedetomidine (Dex), a highly selective 
α2-adrenergic receptor agonist, is widely used for seda-
tion in intensive care units and in clinical anesthesia 
(Carollo et  al. 2008). Dex also has good perioperative 
hemodynamic stability and reduces intraoperative 
anesthetic requirements (Arcangeli et  al. 2009). Ear-
lier research has shown that Dex can regulate systemic 
inflammatory response by decreasing the synthesis of 
proinflammation cytokines, such as TNF-α, IL-6, and 
IL-1β (Hofer et  al. 2009; Taniguchi et  al. 2008). Other 
studies have shown that the anti-inflammatory mecha-
nism of Dex may be associated with a reduction in the 
central sympathetic tone by stimulating central α2 recep-
tors in the medulla oblongata (Pandharipande et al. 2007; 
Rittirsch et  al. 2008), resulting in the balance shifts to 
the benefit of the parasympathetic nervous system. This 
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phenomenon activates the efferent vagus nerve, leading 
to the suppression of biosynthesis and release of pro-
inflammatory cytokines. This efferent neural signaling 
pathway is termed the cholinergic anti-inflammatory 
pathway (Borovikova et  al. 2000), a neurophysiologi-
cal mechanism that regulates the immune system via 
the release of acetylcholine, which can interact with 
α7nAchR expressed by macrophages and other cytokine-
producing cells, resulting in the inhibition of NF-κB acti-
vation and proinflammatory cytokines synthesis, thereby 
preventing tissue damage (Parrish et al. 2008; Saeed et al. 
2005; Tracey 2007). A previous investigation has shown 
that the effects of vagal stimulation on serum TNF, IL-6, 
and IL-1 β production were lost in α7nAChR knockout 
animals, confirming that the receptor is the key in the 
vagal mechanisms of immunosuppression (Wang et  al. 
2003).
Extensive earlier investigations have reported that 
spleen, the main source of circulating pro-inflamma-
tory cytokines, is the target organ of the vagus nerve 
for controlling pro-inflammatory cytokine produc-
tion (Huston et al. 2006; Rosas-Ballina et al. 2008). An 
anatomical study has shown that the common coeliac 
branch of the vagus nerve carries the parasympathetic 
fibers to the splenic ganglion. Selective nerve interrup-
tion further confirms it to be the branch responsible for 
the efferent arm of the anti-inflammatory pathway to 
the spleen (Huston et al. 2006). Thus, we hypothesized 
that Dex may activate the cholinergic anti-inflamma-
tory pathway, thereby inhibiting inflammatory cytokine 
synthesis in spleen, resulting in reduced overwhelm-
ing inflammatory responses to sepsis. However, few 
studies have proven this hypothesis. In this study, we 
used a mice model of lipopolysaccharide (LPS)-acti-
vated sepsis, mimicking what occurs in clinical sepsis, 
to investigate the effects of Dex and α-Bgt on spleen 
TNF-α, IL-6, and IL-1β release in  vivo. To the best of 
our knowledge, this study is the first one that may con-




Male BALB/c mice weighing 18–20 g were obtained from 
Chang Zhou Cavens Laboratory Animal Ltd. (Chang-
zhou, China). The animals were kept at 23  °C with 12 h 
light/12 h dark cycles each day and allowed free access to 
water and food. The investigation was in compliance with 
the Guide for the Care and Use of Laboratory Animals 
published by the National Institutes of Health, and all 
experiments were approved by the Institutional Animal 
Care and Use Committee of Binzhou Medical University 
(Yantai, China).
Chemicals
Dex was obtained from Jiangsu Hengrui Medicine Co., 
Ltd. (Jiangsu, China). Mouse TNF-α, IL-6, and IL-1β 
assay kits were purchased from Shanghai Lengton Bio-
science Co., Ltd. (Shanghai, China). LPS (Escherichia coli 
0111: B4) and α-Bgt were purchased from Sigma Chemi-
cal Co. (St. Louis, MO, USA). Nuclear and cytoplas-
mic protein extraction reagent kits were obtained from 
Beyotime Institute of Biotechnology (Shanghai, China). 
Anti-TNF-α, anti-IL-6, anti-IL-1β, anti-p-IκB p65, anti-
IκB p65, anti-NF-κB p65, anti-Lamin B, and anti-β-actin 
monoclonal antibodies were purchased from Cell Signal-
ing Technology (Danvers, MA, USA). All other chemicals 
were reagent grade.
Experimental design
In the other experiments, mice were randomly divided 
into five groups (n  =  16 per group): control, LPS, 
Dex  +  LPS, α-Bgt  +  Dex  +  LPS, α-Bgt  +  LPS. Dex 
(40  μg/kg) was administered intraperitoneally 15  min 
prior to LPS (10  mg/kg) challenge, α-Bgt (1  μg/kg) was 
added 15  min before LPS or Dex, and control group 
mice received only normal saline. The chosen doses 
of these drugs were based on our preliminary experi-
ments and previous studies (Xiang et  al. 2014). About 
2 h after saline/LPS administration, the 16 mice of each 
group were randomly divided equally into two, and all 
mice were sacrificed with an overdose of pentobarbital 
(60–90 mg/kg) injected intraperitoneally. Serum samples 
were collected immediately. Part 1 was used for spleen 
inflammatory cytokine determination and immunohis-
tochemical examination. The superior part of the spleen 
tissues was harvested, placed in appropriate amount of 
precooled PBS, and homogenized immediately. Then, the 
homogenate was centrifuged at 4 °C, and the supernatant 
was collected for further analysis of TNF-α, IL-6, and 
IL-1β. At the same time, the lower part of spleen tissues 
was harvested for immunohistochemical examination. 
Part 2 was left for real-time polymerase chain reaction 
(RT-PCR) assay and Western blotting. The superior part 
of the spleen tissues was used to extract total RNA for 
RT-PCR measurement, and the lower part of the spleen 
tissues were used to extract nuclear and cytoplasmic pro-
teins for Western blotting.
ELISA assay for TNF‑α, IL‑6, and IL‑1β in serum
Serum samples were collected for TNF-α, IL-6, and IL-1β 
detection. According to the manufacturer’s instructions, 
the concentrations of all cytokine (TNF-α, IL-6, and 
IL-1β) were detected by ELISA kits. A standard curve was 
constructed using various dilutions of TNF-α, IL-6, and 
IL-1β standard preparation. The levels of these cytokines 
were calculated according to standard curves.
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ELISA assay for TNF‑α, IL‑6, and IL‑1β in spleen 
homogenates
Mice spleen tissues were placed in an appropriate amount 
of precooled PBS and then homogenized to determine 
the levels of inflammation cytokines. TNF-α, IL-6, and 
IL-1β in spleen homogenates were measured using com-
mercially available ELISA kits. The levels of TNF-α, IL-6, 
and IL-1β were calculated according to standard curves.
RT‑PCR assay for TNF‑α, IL‑6, and IL‑1β mRNA expression 
in spleen tissues
The levels of TNF-α, IL-6, and IL-1β mRNA in spleen tis-
sues were detected by RT-PCR. Total RNA from spleen tis-
sues was extracted using Trizol reagent. First-strand cDNA 
was synthesized following the manufacturer’s instructions 
for a Transcriptor One Step RT-PCR Kit (Roche, Switzer-
land). The primers were as follows: TNF-α, forward CAC 
CACCATCAAGGACTCAA, reverse GAGACAGAG 
GCAACCTGACC; IL-6, forward CGGAGAGGAGAC 
TTCACAGAG, reverse CATTTCCACGATTTCCCAGA; 
IL-1β, forward CTCACAAGCAGAGCACAAGC, reverse 
TCCAGCCCATACTTTAGGAAGA; β-actin, forward 
GTGCTATGTTG CTCTAGACTTCG, reverse ATGCCA 
CAGGATTCCATACC. We calculated the mean fold 
change in the expression of TNF-α, IL-6, and IL-1β mRNA 
in the experimental group compared with the control 
group. β-Actin was used as the reference gene. Results were 
expressed as relative fold compared with control animals.
Immunohistochemical assay for NF‑κB p65 activation
NF-κB p65 protein activation was observed by immu-
nohistochemistry technique. In a typical procedure, 
sections were microwaved for antigen retrieval and 
pretreated with 0.3  % H2O2. Subsequently, the sec-
tions were blocked with goat serum and incubated in 
a primary antibody solution containing rabbit anti-
NF-κB p65 antibody overnight at 4  °C. After washing, 
the samples were incubated in a suitable secondary 
antibody solution for 1 h at room temperature. Finally, 
the sections were incubated in HRP—streptavidin for 
1  h at room temperature, and the color reaction was 
developed with diaminobenzidine. The sections were 
counterstained, dehydrated, and analyzed under a 
light microscope. The degree of NF-κB activation was 
expressed as percentage of nuclear NF-κB p65 positive 
cells to total alveolar epithelial cells.
Western blotting for TNF‑α, IL‑6, IL‑1β,NF‑κB p65, p‑IκB, 
and IκB
The levels of TNF-α, IL-6, IL-1β, NF-κB p65, p-IκB, and 
IκB protein in spleen tissues were assayed by Western 
blotting. The proteins were separated on 10  % SDS—
polyacrylamide gels and transferred onto a PVDF 
membrane. After blocking the nonspecific site, the 
membrane was incubated overnight with specific pri-
mary antibody at 4  °C. Subsequently, the membrane 
was washed using TBS with Tween (TBST) and then 
incubated with the secondary antibody conjugated with 
horseradish peroxidase at room temperature for 1  h. 
Blots were again washed with TBST and then developed 
with the ECL Plus Western Blotting Detection System 
(Amersham Life Science, UK).
Results
Effects of Dex and α‑Bgt on serum TNF‑α, IL‑6, and IL‑1β
As illustrated in Fig.  1, LPS administration obviously 
enhanced serum concentrations of TNF-α, IL-6, and 
IL-1β, whereas pretreatment with Dex obviously reduced 
these cytokines’ contents in serum. Furthermore, the 
decrease induced by Dex could be substantially reversed 
by preemptive administration with α-Bgt. No significant 
differences were found between α-Bgt  +  LPS and LPS 
groups in terms of the serum levels of TNF-α, IL-6, and 
IL-1β.
Effects of Dex and α‑Bgt on TNF‑α, IL‑6, and IL‑1β levels 
in spleen tissues
As shown in Figs.  2 and 3, we found that pretreatment 
with Dex efficiently suppressed the LPS-induced increase 
in TNF-α, IL-6, and IL-1β in spleen tissues. However, 
the protective effects were obviously reversed by α-Bgt, 
resulting in elevated TNF-α, IL-6, and IL-1β produc-
tion. No statistical differences existed between the 
α-Bgt + LPS and LPS groups for TNF-α, IL-6, and IL-1β 
expression in spleen.
Effects of Dex and α‑Bgt on TNF‑α, IL‑6, and IL‑1β mRNA 
expression in spleen tissues
To gain further insight into the anti-inflammatory mech-
anism of Dex, we determined the mRNA levels of TNF-α, 
IL-6, and IL-1β. As shown in Fig. 4, Dex attenuated the 
LPS-activated increase in TNF-α, IL-6, and IL-1β mRNA 
secretion. Moreover, the inhibitory effects of Dex were 
abated by α-Bgt.
Effects of Dex and α‑Bgt on LPS‑induced NF‑κB p65 
activation
Based on the above conclusions, we next explored 
whether the upstream NF-κB signal transduction path-
way was also involved. Nuclear positive staining repre-
sents the activated form of NF-κB. As shown in Fig.  5, 
our results indicated that nuclear positive staining was 
elevated in septic mouse stimulated with LPS, whereas 
preemptive injection of Dex significantly reduced nuclear 
positive staining. Moreover, the inhibitory effects of Dex 
could be significantly abrogated by α-Bgt, leading to 
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an increase in the percentage of cells showing nuclear 
positive staining. No statistical differences were found 
between α-Bgt + LPS and LPS groups in terms of nuclear 
positive staining in spleen tissues.
Effects of Dex and α‑Bgt on LPS‑induced IκB 
phosphorylation and NF‑κB p65 activation
As previous studies have shown, activated NF-κB 
should translocate to the nucleus and bind to the 
Fig. 1 ELISA assay for serum TNF-α (a), IL-6 (b) and IL-1β (c). Data represented the mean ± SEM (n = 8). **p < 0.01 compared to control group; 
##p < 0.01 compared to LPS group; ^^p < 0.01 compared to Dex + LPS group
Fig. 2 ELISA assay for TNF-α (a), IL-6 (b) and IL-1β (c) concentrations in spleen homogenates. Data represented the mean ± SEM (n = 8). **p < 0.01 
compared to control group; ##p < 0.01 compared to LPS group; ^^p < 0.01 compared to Dex + LPS group
Fig. 3 Western blotting assay for TNF-α (a), IL-6 (b) and IL-1β (c) levels in spleen tissues. Data represented the mean ± SEM (n = 8). **p < 0.01 com-
pared to control group; ##p < 0.01 compared to LPS group; ^^p < 0.01 compared to Dex + LPS group
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promoter region of multiple genes, including cytokine 
genes, thereby inducing the expression of cytokine 
mRNA and protein [19,20]. As shown in Fig.  6, the 
translocation of NF-κB p65 to nucleus and IκB phos-
phorylation in spleen significantly increased 2  h after 
LPS challenge. Moreover, Dex administration prior to 
LPS decreased NF-κB p65 activation and IκB phos-
phorylation compared with the LPS group. However, 
all these decreases were blocked by α-Bgt pretreat-
ment in the α-Bgt +  Dex +  LPS group. No statistical 
differences were observed between α-Bgt  +  LPS and 
LPS groups in terms of NF-κB p65 activity and IκB 
phosphorylation.
Discussion
During sepsis, pro-inflammatory cytokines are known 
to be released largely unopposed, which leads to patho-
logical injuries (Raetz and Whitfield 2002). In the present 
study, data showed that serum TNF-α, IL-6, and IL-1β 
increased following LPS administration, and preventive 
treatment with Dex relieved the stimulated rise in cir-
culating levels of these pro-inflammatory cytokines. The 
Fig. 4 RT-PCR assay for TNF-α (a), IL-6 (b) and IL-1β (c) mRNA in spleen tissues. The levels of Data represented the mean ± SEM (n = 8). **p < 0.01 
compared to control group; ##p < 0.01 compared to LPS group; ^^p < 0.01 compared to Dex + LPS group
Fig. 5 Immunohistochemical assay for NF-κB p65 activation in spleen tissues. Control group (a); LPS group (b); Dex + LPS group (c); 
α-Bgt + Dex + LPS group (d); α-Bgt + LPS group (e): magnification ×400. The percentage of nuclear NF-κB positive cells in spleen (f). Data rep-
resented the mean ± SEM (n = 8). **p < 0.01 compared to control group; ##p < 0.01 compared to LPS group; ^^p < 0.01 compared to Dex + LPS 
group
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obvious and rapid decline in the levels of these mediators 
may contribute to a reduction in multiple organ dysfunc-
tions, resulting in an improvement of outcome in septic 
mice. Moreover, preventive injection of α-Bgt reversed 
the Dex-induced reduced severity of experimental sep-
sis, consistent with several original studies that have 
also shown Dex possessing anti-inflammatory capacity 
by activating the cholinergic anti-inflammatory pathway 
(Xiang et al. 2014).
Removing the spleen itself also reportedly lowers the 
production and plasma levels of inflammatory cytokines 
to the same degree as does vagal stimulation when spleen 
is intact. Thus, spleen is essential for inflammatory reg-
ulation in the cholinergic anti-inflammatory pathway 
(Ramsay and Luterman 2004). However, no studies have 
been conducted so far to study the role of spleen in the 
anti-inflammatory effects of Dex. To investigate the spe-
cific functions of spleen in the protective effects of Dex, 
we analyzed the changes in pro-inflammatory cytokine 
levels in spleen. Dex stimuli was found to suppress the 
production of TNF-α, IL-6, and IL-1β in spleen, and 
α-Bgt administration up-regulated the protein expres-
sion levels of these cytokines. Considering these data, 
our results suggested that the regulation of serum TNF-
α, IL-6, and IL-1β was correlated with the expression of 
these cytokines in spleen.
To further investigate how the preemptive administra-
tion of Dex modulated inflammation, we measured the 
effects of Dex and α-Bgt on the levels of TNF-α, IL-6, 
and IL-1β mRNA in spleen. RT-PCR analysis revealed 
that LPS administration elevated the gene production 
of these cytokines in spleen and that pretreatment with 
Dex inhibited splenic TNF-α, IL-6, and IL-1β mRNA 
expression. However, pretreatment with α-Bgt attenu-
ated the anti-inflammatory benefits of Dex, resulting in 
elevated splenic TNF-α, IL-6, and IL-1β mRNA release.
Most inflammatory signals are known to merge in the 
activation of the NF-κB pathway, and NF-κB has been 
shown to play a critical role in modulating mortality in 
experimental and clinical sepsis (Böhrer et al. 1997). We 
next determined whether the upstream NF-κB signal 
transduction pathway was also involved. NF-κB is a pro-
tein transcription factor and typically a heterodimer of 
p50 and p65 subunits. It plays a pivotal role in immune 
and inflammatory responses by regulating the expression 
of several proteins, including pro-inflammatory cytokines, 
chemokines, and adhesion molecules. Uncontrolled acti-
vation of the NF-κB pathway is involved in the pathogen-
esis of many acute and chronic inflammatory diseases. In 
its inactive state, the NF-κB dimer is present in the cyto-
sol, where it is bound to an inhibitory protein, IκB. Several 
stimuli could induce the release and degradation of the 
inhibitory protein IκB from the dimeric complex (Baeu-
erle and Baltimore 1988), triggering a series of signaling 
events that result in NF-κB activation (Müller et al. 1993). 
Subsequently, multiple molecules involved in inflamma-
tory responses, including TNF-α, IL-6, and IL-1β, are 
synthesized. Our research showed that LPS treatment 
enhanced IκB phosphorylation and NF-κB p65 activation 
in spleen and that Dex treatment hampered it. Further 
analysis using the selective α7nAChR antagonist α-Bgt 
indicated that α7nAChR activation was responsible for 
the decrease in IκB phosphorylation and NF-κB p65 acti-
vation. This finding corresponded with a previous report 
showing a similar blunting of the NF-κB pathway on the 
activation of the cholinergic anti-inflammatory pathway.
Fig. 6 Western blotting assay for NF-κB p65 nuclear translocation and IκB phosphorylation in spleen tissues. The levels of NF-κB p65 in nucleus 
(a), NF-κB p65 in cytoplasm (b) and p-IκB/IκB in cytoplasm (c). Data represented the mean ± SEM (n = 8). **p < 0.01 compared to control group; 
##p < 0.01 compared to LPS group; ^^p < 0.01 compared to Dex + LPS group
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To our knowledge, this report provided evidence for 
the first time that Dex inhibited NF-κB p65 activation 
and lowered the TNF-α, IL-6, and IL-1β expression in 
levels of protein and mRNA in spleen. Conversely, pre-
treatment with α-Bgt reversed the anti-inflammatory 
capacity of Dex. According to the obtained results, we 
concluded that the Dex-mediated systemic inflammatory 
response could be due at least partly to the activation of 
the cholinergic anti-inflammatory pathway, resulting in 
decreased NF-κB activation and inflammatory cytokine 
production in spleen, thereby reducing the serum con-
centrations of inflammatory cytokines and attenuating 
the inflammatory responses of septic mice.
Conclusion
Our findings demonstrated the important role of spleen 
in the protective effects of Dex against sepsis and pro-
vided further insight into the anti-inflammatory mecha-
nisms of Dex. Preemptive administration of Dex was 
sufficiently potent to reduce inflammatory responses in 
LPS-induced sepsis, and future research should focus on 
finding clinical evidence to support the use of Dex as an 
anti-inflammatory adjuvant in humans.
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